Recent U.S. drug alerts: Turning emerging evidence into workforce preparedness

Recent United States alerts on synthetic opioids, sedating adulterants and concentrated opioid products have practical implications across prevention, treatment, recovery support, public health and drug supply reduction. For the U.S. professional community, they warrant a review of local preparedness and information-sharing arrangements. For ISSUP colleagues elsewhere, they offer an opportunity to learn from emerging threats while checking carefully what is relevant to their own settings.

The alerts concern both newly emerging substances and changing patterns involving established drugs. Their value lies in helping professionals recognise when existing knowledge, testing or service arrangements may need updating.

What are the recent U.S. alerts telling us?

• Fentanyl analogues remain a significant concern. On 15 September 2026, the Office of National Drug Control Policy (ONDCP) issued a notice highlighting carfentanil, fluorofentanyl and methylfentanyl. It reports laboratory detections across all four U.S. regions and warns that routine hospital testing may miss these substances. For practitioners, this means that a negative routine screen should not close the enquiry when someone presents with signs of opioid overdose. Clinical teams should establish what their local tests can detect and when more specialised testing is available. Across treatment, prevention and recovery services, the alert also provides a reason to revisit overdose-response training, naloxone access and emergency referral arrangements. This broadens the context of our earlier discussion of carfentanil in selected counterfeit tablets and powders, while reminding us to check how national findings relate to local conditions. Read the ONDCP notice.
• Medetomidine creates challenges during both intoxication and withdrawal. The 2 April 2026 CDC/ONDCP advisory described increasing detection of medetomidine, a non-opioid sedative, in the illicit fentanyl supply. Exposure can cause profound sedation, slow heart rate and low blood pressure. Withdrawal after regular exposure can involve severe agitation, high blood pressure and other complications requiring emergency or intensive care. Naloxone remains essential for suspected accompanying opioid overdose, but it does not reverse medetomidine’s effects. We therefore need to pay attention to persistent sedation after naloxone and to severe or unexpected symptoms when someone stops using a product. Clinical teams should seek toxicology advice where indicated, while community and recovery practitioners should know how to arrange urgent assessment. These presentations should not be assumed to follow the usual course of opioid intoxication or withdrawal. Read the CDC advisory.
• Cychlorphine illustrates the emergence of further synthetic-opioid families. An ONDCP notice dated 30 April 2026 highlighted this substance, also called N-propionitrile chlorphine, from the “orphine” family. The notice reported detections in 10 states during 2025 and links to at least 55 deaths during 2025–2026. These figures describe reported findings, rather than the full extent of exposure. Cychlorphine may occur alone or alongside other substances, and routine hospital opioid screens may not identify it. For practitioners, the useful step is to recognise that testing focused on familiar opioids can leave gaps. Unexplained or unusual overdose presentations should prompt discussion with laboratory and toxicology colleagues and reporting through appropriate local channels. Services should also review their readiness to provide repeated naloxone doses when required under emergency protocols, alongside urgent medical care. Read the ONDCP notice.
• Mixtures complicate recognition and response. The DEA’s 12 May 2026 advisory drew attention to fentanyl combined with nitazenes, cychlorphine, xylazine and medetomidine. Such combinations can produce overlapping opioid and non-opioid effects, so improvement after naloxone does not necessarily mean that the emergency has resolved. Continued assessment and support for breathing, consciousness and circulation remain important. In our conversations with people using services, we should ask what they believed they were taking, whether the effects differed from previous experiences, and whether other substances were used. These accounts can help guide assessment, although they cannot confirm a product’s contents. Sharing unusual patterns through agreed clinical and public-health channels can help connect individual encounters with a wider local signal. Read the DEA advisory.
• Concentrated 7-hydroxymitragynine products also warrant attention. FDA warnings address products containing added or enhanced 7-OH, including tablets, gummies and shots, with reported harms including dependence, withdrawal and seizures. A July 2026 update also discussed related synthetic compounds. Professionals should distinguish these concentrated products from the trace quantities of 7-OH naturally occurring in kratom leaf. In practice, this means asking about the specific product, reviewing packaging or photographs where available, and recording any stated 7-OH content, amount consumed and frequency of use. It is also useful to ask why the person is taking it, including whether they are trying to manage pain, anxiety or opioid withdrawal, as this can open a conversation about unmet treatment needs. Terms such as “kratom” or “extract” should prompt further enquiry; labels alone cannot verify composition. Where contents remain uncertain, practitioners should document this and seek advice from poison centres or toxicology services as appropriate. Read the FDA consumer warning and July update.

Together, these alerts extend the discussion in our previous post, The product may not be what it says. Each points to practical considerations for assessment, communication and care. The shared challenge is making sure that this information reaches the right people and leads to a proportionate response.

For U.S. communities of practice, a useful starting point is a brief team discussion: which of these findings are relevant locally, what do we already have in place, and where are the gaps? The actions outlined above can then be assigned to someone, with a timeframe for follow-up. This might involve clarifying access to specialist advice, updating referral information or checking that an alert has reached colleagues working outside specialist substance use services. Teams should also agree when new evidence would warrant a further review.

We should make room in these discussions for prevention practitioners, peer workers, recovery professionals and people with lived and living experience. Their observations and questions can help identify information that is unclear, barriers to seeking care and concerns that services may otherwise overlook. These contributions can guide further enquiry alongside clinical, laboratory and public-health findings. Managers can support this exchange by ensuring that staff know both where to raise a concern and how they will hear back about it.

One distinction worth carrying forward is between hospital testing and community drug checking: each has its own scope and limitations. A February 2026 UNODC warning explains that nitazene strips may miss some analogues and that fentanyl and nitazene strips do not detect orphines. When discussing results, we should be clear about what was tested for, what remains uncertain and what follow-up is appropriate. A negative result should never be presented as assurance that an unknown product is safe.

For the global ISSUP community, these U.S. alerts offer an opportunity to examine our own preparedness. They do not establish that the same substances are necessarily circulating in another country and to what extent. National Chapters and professional networks can help colleagues assess local relevance by consulting national authorities, laboratories and available surveillance systems before adapting messages or recommending changes. Where specialist resources are limited, a feasible first step may be to strengthen documentation, identify a referral contact and establish a reliable route for reporting unusual presentations.

This is also where translation into local practice requires care. Guidance needs to account for the workforce’s responsibilities, available services, language and access to emergency care or testing. A recommendation is more useful when colleagues can see how to act on it in their setting. Our reflections from Mauritius explore the importance of interpreting evidence in context, while the 2026 UNODC World Drug Report webinar offers a wider perspective on regional and global developments.

Staying abreast of alerts and trends should therefore become a manageable, routine part of professional development. Organisations could nominate someone to review trusted sources regularly and bring relevant updates into supervision, team meetings and continuing education, with urgent warnings shared promptly. A short briefing can explain what has changed, how strong the evidence is, who needs to know and what action is proposed. Dating these briefings and revisiting them when evidence changes can help prevent an older warning from being circulated as a new development.

Useful sources include the CDC Health Alert Network, ONDCP drug threat notices, CFSRE NPS Discovery and UNODC’s Early Warning Advisory, alongside national and local systems. Reading alerts together with trend reports helps us consider whether a finding is isolated, recurring or part of a broader change, while remaining mindful of differences in sampling and reporting.

As ISSUP’s workforce expands across countries and disciplines, Knowledge Share and our professional Networks can support this exchange. Members can contribute verified alerts and accounts of what their teams changed, what proved workable and what remains unresolved, without sharing identifying information. Retaining the source, date, location and evidence limitations allows colleagues to judge relevance for themselves. Sharing the practical response alongside the alert makes our collective learning more useful to the people, families and communities we serve.